CL2021003011A1 - Formas cristalinas de n–[4–(clorodifluorometoxi)fenil]–6–[(3r)–3–hidroxipirrolidin–1–il]–5–(1h–pirazol–5–il)piridina–3–carboxamida - Google Patents
Formas cristalinas de n–[4–(clorodifluorometoxi)fenil]–6–[(3r)–3–hidroxipirrolidin–1–il]–5–(1h–pirazol–5–il)piridina–3–carboxamidaInfo
- Publication number
- CL2021003011A1 CL2021003011A1 CL2021003011A CL2021003011A CL2021003011A1 CL 2021003011 A1 CL2021003011 A1 CL 2021003011A1 CL 2021003011 A CL2021003011 A CL 2021003011A CL 2021003011 A CL2021003011 A CL 2021003011A CL 2021003011 A1 CL2021003011 A1 CL 2021003011A1
- Authority
- CL
- Chile
- Prior art keywords
- chlorodifluoromethoxy
- hydroxypyrrolidin
- pyrazol
- carboxamide
- pyridine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención describe formas cristalinas específicas de N–[4–(Clorodifluorometoxi)fenil]–6–[(3R)–3–hidroxipirrolidin–1–il]–5–(1H–pirazol–5–il)piridina–3–carboxamida. La presente invención además se refiere a métodos para preparar dichas formas cristalinas, a composiciones farmacéuticas que comprenden dichas formas cristalinas, y métodos de uso de dichas formas cristalinas y composiciones farmacéuticas para tratar enfermedades
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962848857P | 2019-05-16 | 2019-05-16 | |
US201962949599P | 2019-12-18 | 2019-12-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021003011A1 true CL2021003011A1 (es) | 2022-09-09 |
Family
ID=70775449
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021003011A CL2021003011A1 (es) | 2019-05-16 | 2021-11-15 | Formas cristalinas de n–[4–(clorodifluorometoxi)fenil]–6–[(3r)–3–hidroxipirrolidin–1–il]–5–(1h–pirazol–5–il)piridina–3–carboxamida |
Country Status (13)
Country | Link |
---|---|
US (3) | US11407735B2 (es) |
EP (1) | EP3969117A1 (es) |
JP (1) | JP2022532404A (es) |
KR (1) | KR20220009414A (es) |
CN (1) | CN114144232A (es) |
AU (1) | AU2020276701B2 (es) |
BR (1) | BR112021022712A2 (es) |
CA (1) | CA3139812A1 (es) |
CL (1) | CL2021003011A1 (es) |
IL (1) | IL287995A (es) |
MX (1) | MX2021013970A (es) |
TW (1) | TW202110823A (es) |
WO (1) | WO2020230099A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4096790A1 (en) | 2020-01-28 | 2022-12-07 | Teva Pharmaceuticals International GmbH | Solid state forms of asciminib and processes for the preparation thereof |
WO2022206937A1 (zh) * | 2021-04-01 | 2022-10-06 | 苏州晶云药物科技股份有限公司 | 一种吡唑取代的烟酰胺类化合物的盐酸盐新晶型及其制备方法 |
CN114369085B (zh) * | 2021-12-27 | 2023-01-03 | 武汉九州钰民医药科技有限公司 | 盐酸Asciminib的制备方法 |
WO2024100212A1 (en) | 2022-11-10 | 2024-05-16 | Synthon B.V. | Crystalline form of asciminib hydrochloride |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2930501A (en) * | 2000-01-07 | 2001-07-24 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
CA2871715A1 (en) | 2012-05-15 | 2013-11-21 | Novartis Ag | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 |
MA37519B1 (fr) * | 2012-05-15 | 2017-03-31 | Novartis Ag | Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1 |
EP3233918A1 (en) | 2014-12-19 | 2017-10-25 | Novartis AG | Combination therapies |
EP3120851A1 (en) | 2015-07-21 | 2017-01-25 | Pangaea Biotech S.L. | 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers |
US9931342B2 (en) | 2016-02-02 | 2018-04-03 | Duke University | Compositions and methods for the treatment of cancer |
EP3292870A1 (en) | 2016-09-08 | 2018-03-14 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Fibronectin for use in the treatment of leukemia |
CN109715616A (zh) | 2016-09-27 | 2019-05-03 | 诺华股份有限公司 | 用于结晶有机化合物的表面活性剂体系 |
CN111556747B (zh) | 2017-10-27 | 2023-11-17 | 索尼克马斯特有限公司 | 用于调节肌肉功能的dux4诱导的抑制剂 |
US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
-
2020
- 2020-05-14 US US16/874,622 patent/US11407735B2/en active Active
- 2020-05-14 TW TW109116067A patent/TW202110823A/zh unknown
- 2020-05-15 MX MX2021013970A patent/MX2021013970A/es unknown
- 2020-05-15 KR KR1020217040723A patent/KR20220009414A/ko unknown
- 2020-05-15 EP EP20726959.8A patent/EP3969117A1/en active Pending
- 2020-05-15 WO PCT/IB2020/054628 patent/WO2020230099A1/en active Application Filing
- 2020-05-15 BR BR112021022712A patent/BR112021022712A2/pt unknown
- 2020-05-15 AU AU2020276701A patent/AU2020276701B2/en active Active
- 2020-05-15 JP JP2021568319A patent/JP2022532404A/ja not_active Withdrawn
- 2020-05-15 CN CN202080051576.4A patent/CN114144232A/zh active Pending
- 2020-05-15 CA CA3139812A patent/CA3139812A1/en active Pending
-
2021
- 2021-11-10 IL IL287995A patent/IL287995A/en unknown
- 2021-11-15 CL CL2021003011A patent/CL2021003011A1/es unknown
-
2022
- 2022-07-06 US US17/858,701 patent/US20230089503A1/en active Pending
- 2022-07-06 US US17/858,713 patent/US20230074064A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200361904A1 (en) | 2020-11-19 |
AU2020276701A8 (en) | 2022-05-12 |
US11407735B2 (en) | 2022-08-09 |
US20230074064A1 (en) | 2023-03-09 |
CA3139812A1 (en) | 2020-11-19 |
WO2020230099A1 (en) | 2020-11-19 |
KR20220009414A (ko) | 2022-01-24 |
BR112021022712A2 (pt) | 2022-03-29 |
JP2022532404A (ja) | 2022-07-14 |
AU2020276701A1 (en) | 2022-01-06 |
TW202110823A (zh) | 2021-03-16 |
US20230089503A1 (en) | 2023-03-23 |
CN114144232A (zh) | 2022-03-04 |
AU2020276701B2 (en) | 2023-11-23 |
MX2021013970A (es) | 2022-01-04 |
IL287995A (en) | 2022-01-01 |
EP3969117A1 (en) | 2022-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021003011A1 (es) | Formas cristalinas de n–[4–(clorodifluorometoxi)fenil]–6–[(3r)–3–hidroxipirrolidin–1–il]–5–(1h–pirazol–5–il)piridina–3–carboxamida | |
MX2019011785A (es) | Proceso para preparar compuestos de 2,3-dihidrotiazolo[3,2-a]pirim idin-4-io quirales. | |
PH12018500264A1 (en) | 2-(het)aryl-substituted condensed heterocyclic derivatives as pest control agents | |
MX2015009855A (es) | Nuevos compuestos sustituidos con halogeno. | |
PH12018500638A1 (en) | 2-(het)aryl-substituted condensed bicyclic heterocyclic derivatives as pest control agents | |
CY1124085T1 (el) | Κρυσταλλικα αλατα (s)-6-((1-ακετυλπιπεριδιν-4-υλ)αμινο)-ν-(3-(3,4-διυδροϊσοκινολιν-2(1η)-υλ)-2-υδροξυπροπυλ)πυριμιδινο-4-καρβοξαμιδιου | |
MY175845A (en) | Substituted benzamides for treating arthropodes | |
CR20200617A (es) | Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2 | |
EA201301319A1 (ru) | Производные пиридин-2(1н)-она, применимые в качестве лекарственных средств для лечения миелопролиферативных нарушений, отторжения трансплантата, иммунологически обусловленных и воспалительных заболеваний | |
GEP20156285B (en) | Compounds and compositions as trk inhibitors | |
EA201400701A1 (ru) | Замещенные соединения пиразоло[1,5-a]пиридина в качестве ингибиторов тропомиозинрецепторной киназы (trk) | |
MX2018013191A (es) | Compuestos de pirimidina como inhibidores de la quinasa jak. | |
EA202091016A1 (ru) | Пиримидиновое соединение в качестве ингибитора jak киназы | |
AR085324A1 (es) | Composiciones de moleculas pesticidas y proceso de aplicacion de dichas composiciones para controlar acaros, insectos y otras plagas | |
PH12019500497A1 (en) | Heteroaryl carboxamide compounds as inhibitors of ripk2 | |
EA201500182A1 (ru) | 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ | |
EA201890827A1 (ru) | Конденсированные производные пиразола в качестве ингибиторов киназы | |
CO2017013226A2 (es) | Procesos e intermediarios para la preparación de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo | |
AU2016320892A8 (en) | Salts of a Pim kinase inhibitor | |
NZ719749A (en) | Pesticidal compositions and related methods | |
MX2015013414A (es) | N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa. | |
NZ719952A (en) | Pesticidal compositions and related methods | |
PH12020500312A1 (en) | Method of controlling rice pests in rice | |
MX2018007219A (es) | Metodos para preparacion de compuestos heterociclicos de 1,3-benzodioxol. | |
EA201400214A1 (ru) | Антраниламидные соединения и их применение в качестве пестицидов |